Clinical trials: B-cell Malignancies
Chronic Lymphocytic Leukemia
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This is an open-label, multicenter, Phase I/II study of the safety of escalating doses of single-agent PRO131921 in patients with chronic lymphocytic leukemia (CLL) who have relapsed after or were refractory to treatment with a…
- Trial name
- NCT00496132
- Testing
- PRO131921
- Volunteers
- 16 people
- Sponsor
- Genentech, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients
This study will assess the safety and preliminary efficacy of escalating doses of VAY736 in relapsed or refractory CLL patients.
- Trial name
- VAY736Y (NCT02137889)
- Testing
- VAY736
- Where
- 2 sites in United States, Spain
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Patients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16 patients (nodular, diffuse large cell, mantle cell plus…
- Trial name
- NCT00446095
- Testing
- fostamatinib
- Where
- 11 sites in United States
- Volunteers
- 81 people
- Sponsor
- Rigel Pharmaceuticals
Diffuse Large B Cell Lymphoma
TREatment of degeNerative and Neoplastic Diseases With Rituximab
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of PBO-326 (Rituximab) and Mabthera (Rituximab) in…
- Trial name
- TREND (NCT01277172)
- Testing
- Rituximab
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Probiomed S.A. de C.V.
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00014664
- Testing
- apolizumab
- Where
- United States
- Sponsor
- PDL BioPharma, Inc.
Diffuse Large B Cell Lymphoma，DLBCL
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Purinostat mesylate for injection (PM) was the novel and highly potent Class I a and IIb HDAC-selective inhibitors. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic…
- Trial name
- NCT05526313
- Testing
- Purinostat Mesylate 1.2mg/m^2, Purinostat Mesylate 2.4mg/m^2, Purinostat Mesylate 4.0mg/m^2
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Chronic Lymphocytic Leukemia, B-cell Lymphomas
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
- Trial name
- NCT02891590
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang DTRM Biopharma
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
- Trial name
- NCT07121946
- Testing
- LTZ-301
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- LTZ Therapeutics, Inc.
B-cell Lymphoma
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
This is a single-arm, open-label clinical study evaluating the efficacy and safety of CD20/CD19/CD22 multi-targeted chimeric antigen receptor T-cell (CAR-T) injection in patients with relapsed/refractory B-cell lymphoma.
- Trial name
- NCT07093086
- Testing
- Triple-targeted CAR-T Therapy
- Where
- 2 sites in China
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-3 (NCT06235229)
- Testing
- GC012F
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL
- Trial name
- NCT07896590
- Testing
- Orelabrutinib, ICP-248
- Where
- 46 sites in China
- Volunteers
- 292 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B-cell Lymphoma
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Primary objective: To evaluate the efficacy of recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection(HS006) with CHOP(Hi-CHOP) versus Rituximab with CHOP (R-CHOP) in patients with previously untreated Diffuse…
- Trial name
- Hi-CHOP (NCT03485118)
- Testing
- HS006+CHOP, Rituximab+CHOP
- Volunteers
- 137 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
B-Cell Chronic Lymphocytic Leukemia
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
This is a Phase 3, prospective, multicenter, open-label, randomized, controlled study to evaluate and compare the efficacy and safety of fludarabine plus alemtuzumab versus fludarabine alone as second-line therapy for patients…
- Trial name
- NCT00086580
- Testing
- FluCAM [Fludara + Campath], fludarabine phosphate
- Where
- 48 sites in United States, Austria and 13 more
- Volunteers
- 335 people
- Sponsor
- Genzyme, a Sanofi Company
B-Cell Chronic Lymphocytic Leukemia
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
This is a Phase 2, open-label, multicenter, efficacy, safety, and pharmacodynamic study of CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00485966
- Testing
- CX-3543
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cylene Pharmaceuticals
Diffuse Large B-cell Lymphoma
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment.
- Trial name
- ECHELON-3 (NCT04404283)
- Testing
- Brentuximab vedotin, Rituximab, Lenalidomide
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 240 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Acute Lymphocytic Leukemia
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) (if applicable) of JWCAR029 in…
- Trial name
- NCT05727683
- Testing
- CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Acute Lymphoblastic Leukemia
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02010931
- Where
- 10 sites in Czechia, France and 6 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB)…
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- UCBT (NCT01930162)
- Testing
- HSC835
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia Lymphocytic Chronic B-Cell
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD).
- Trial name
- NCT01732861
- Testing
- CC-292, Lenalidomide
- Where
- 11 sites in United States, Austria
- Volunteers
- 20 people
- Sponsor
- Celgene